Core Viewpoint - Jamf Holding Corp. is under investigation for potential breaches of fiduciary duties by its board of directors in relation to a proposed take-private sale at a price of $13.05 per share, which may be considered unfairly low for shareholders [1][3]. Group 1: Investigation Details - The investigation is led by Bleichmar Fonti & Auld LLP, focusing on whether Jamf's board and Vista Equity Partners have acted in the best interests of shareholders regarding the acquisition by Francisco Partners Management, L.P. [5][3]. - Jamf's board did not form an independent special committee to assess the transaction, raising concerns about conflicts of interest, particularly since Vista owns 34.4% of Jamf's stock and has the right to appoint four out of nine board members [4][3]. Group 2: Shareholder Implications - Current shareholders of Jamf are encouraged to seek additional information and may have legal options available to them, as the firm operates on a contingency fee basis, meaning no upfront costs for shareholders [6][2]. - The acquisition deal is contingent upon a shareholder vote, but Vista has not been excluded from participating in that vote, which could further complicate the situation for minority shareholders [4][3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Capricor Therapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][2]. Group 1: Legal Investigation - The law firm is encouraging long-term stockholders of Capricor who suffered losses between October 9, 2024, and July 10, 2025, to discuss their legal rights [1]. - A class action complaint was filed against Capricor on July 17, 2025, focusing on the company's disclosures regarding its lead cell therapy candidate, deramiocel [2]. - The investigation centers on whether Capricor's board misled investors about the drug's regulatory status and safety data [2]. Group 2: Regulatory Issues - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - The CRL also highlighted outstanding issues in the Chemistry, Manufacturing, and Controls section of the application [3]. Group 3: Stock Performance - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marqeta, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2] Group 1: Lawsuit Details - The class action complaint was filed on December 9, 2024, covering a Class Period from May 7, 2024, to November 4, 2024 [1] - The lawsuit claims that Marqeta made false and misleading statements regarding regulatory challenges and subsequently had to cut its guidance for Q4 2024 [2] - Investors reportedly suffered damages when the true details about Marqeta's business outlook were revealed [2] Group 2: Contact Information - Long-term stockholders of Marqeta are encouraged to contact Bragar Eagel & Squire, P.C. for more information regarding the claims [3] - The law firm offers no cost or obligation for inquiries related to the investigation [3]

Core Viewpoint - Purcell & Lefkowitz LLP is investigating REX American Resources Corporation to determine if its directors breached fiduciary duties related to recent corporate actions [1] Group 1 - The investigation is on behalf of shareholders of REX American Resources Corporation [1] - The law firm specializes in representing shareholders affected by securities fraud and breaches of fiduciary duty [3] - Shareholders seeking more information can contact the firm directly for assistance [2]

Core Viewpoint - Purcell & Lefkowitz LLP is investigating The Ensign Group, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is on behalf of The Ensign Group's shareholders [1]. - The law firm specializes in representing shareholders affected by securities fraud and corporate misconduct [3]. - Shareholders can obtain additional information regarding their rights and options at no cost [2].